This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims**

Claim 1: (previously presented) A pharmaceutical preparation comprising active compound, gelatin and fillers and which is free of organic solvent residues, wherein the active compound consists essentially of levo-thyroxine sodium, whereby said preparation possesses improved stability versus one in which a customary binder other than gelatin is used.

## Claim 2: (canceled)

Claim 3: (previously presented) The pharmaceutical preparation according to claim 1, containing 5 to 400 µg of levothyroxine.

Claim 4: **(previously presented)** The pharmaceutical preparation according to claim 1, containing levothyroxine sodium micronized with a particle size of between 5 µm and 25 µm.

Claim 5: (previously presented) The pharmaceutical preparation according to Claim 1, wherein the filler is lactose, maize starch or microcrystalline cellulose.

Claim 6: (previously presented) The pharmaceutical preparation according to Claim 1, which is a solid preparation in the form of tablets.

Claim 7: (canceled)

Claim 8: (canceled)

Claim 9: (previously presented) A pharmaceutical preparation consisting essentially of

levo-thyroxine sodium, gelatin and fillers which is free of organic solvent residues and which is in

solid form, whereby said preparation possesses improved stability versus one in which a customary

binder other than gelatin is used.

Claim 10: (new) A pharmaceutical preparation comprising active compound, gelatin and

fillers and which is free of organic solvent residues, wherein the active compound consists

essentially of levo-thyroxine sodium and liothyronine sodium, whereby said preparation possesses

3

improved stability versus one in which a customary binder other than gelatin is used.

**MERCK 2168D1**